Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9496 vs Fulvestrant in Pre-surgical Breast Cancer
NCT03236974Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of AZD9496 in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Pharmacodynamics changes to estrogen receptor (ER) expression. Started Oct 2017; status: completed.
02
Drugs
AZD9496
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03236974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236974.